Shingles Vaccine Market – By Product, By Vaccine Type – Global Forecast, 2025 to 2034

Shingles Vaccine Market Size

The global shingles vaccine market was valued at USD 4.9 billion in 2024 and is expected to exhibit growth at a CAGR of 10.1% from 2025 to 2034 period. Increased market growth can be due in part to an expansion in the elderly population, expanding reimbursement facilities, and heightened understanding of shingles and related complications, among others.
 

Shingles, also referred to as herpes zoster, is an illness caused by the varicella-zoster virus, and it mainly affects people who are above 50 years. The likelihood of suffering from shingles and its complications, such as postherpetic neuralgia, becomes higher with increasing age. Shingles vaccination, therefore, is a significant requirement for the elderly. Due to increasing global aging, there is anticipation in the growth of demand for shingles vaccines among this age group.
 

Moreover, public health campaigns and awareness programs have created more understanding about the consequences of suffering from shingles, especially in the elderly. These health organizations are making efforts to help the public understand the necessity of vaccination in the management of shingles and the prevention of extended discomfort. This, in turn, is leading to increased vaccination uptake in the elderly population and caregivers, thereby boosting the growth of the shingles vaccine market.
 

The shingles vaccine is an immunization that prevents the skin rash known as shingles, which is caused by the reactivation of varicella zoster, which is also from chickenpox. The vaccine works by increasing the immune response to the virus, which reduces the chances of a flare-up. This is especially important for older patients, as they are more commonly afflicted by shingles.
 

Shingles Vaccine Market Trends

The new generation of recombinant shingles vaccines is highly effective and has transformed the prevention game against herpes zoster (shingles), especially in older adults who are more at risk for this disease. Recent developments with these vaccines have dealt with the shortcomings of conventional vaccines, like the concerns for weakened immunity in the aging population.
 

• Shingrix and other recombinant shingles vaccines are far better than the live-attenuated vaccines made in the past. The formulation, using targeted proteins from the varicella zoster virus instead of the live viruses, induces immunity without infection, making it suitable for patients with weakened immune systems.
   
• In the pre-clinical and clinical phases, recombinant vaccines were proven to be more than ninety percent effective at preventing shingles in adults above sixty, while also having a lower trigger rate for adverse effects. This has led to global health organizations changing their guidelines to recommend more people to be vaccinated.
   
• The development of vaccines has also increased the duration of vaccine efficacy. Previously, shingles vaccines showed a gradual decline in efficacy with time, which made it necessary to consider additional doses or boosters to overcome this problem.
   
• However, modern recombinant vaccines show improved durability, gap-filling these shortcomings, offering extended protection that is critical for older adults who tend to be at a higher risk of shingles due to declining immune function with age. This extended efficacy reduces the frequency of vaccination needed among older adults, allowing convenience for both patients and the market.
   

Shingles Vaccine Market Analysis

Based on product, the market is classified into Shingrix, Zostavax, and SKYZoster. The Shingrix segment generated the highest revenue of USD 4.2 billion in 2024.
 

• Shingrix aids in the prevention of the infection of shingles with the recombinant vaccines. It is essential for the aged population who suffer greatly from the disease and its complications.
   
• Shingrix further has a stronger duration of efficacy, which makes it easier on the patient, unlike the older vaccines, which had a more moderated range of immunity. This capability of long immune response puts Shingrix on a favorable list, making it a cost-effective solution and hence increasing the adoption rates globally.
   
• Leading experts in health care, including the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), recommend the Shingrix vaccine for all adults over 50 years of age and some immune-deficient groups. These recommendations have led to higher vaccination rates, especially in North America and Europe, where shingles prevention is emphasized.
   
• Moreover, the fact that Shingrix does not use a live virus makes it safe for most people, especially those with weakened immune systems who had fewer options for shingles prevention. The safety and efficacy of Shingrix in these populations have expanded its recommended use and broadened the scope of shingles vaccination, consolidating the market position of Shingrix.
   

Based on vaccine type, the shingles vaccine market is segmented into recombinant vaccine and live attenuated vaccine. The recombinant vaccine segment dominated the market in 2024 and is anticipated to reach USD 11.3 billion by the end of the forecast period.
 

• People at higher risks of developing shingles are proven to benefit from recombinant shingles vaccines, which have more than 90% effectiveness and offer exceptional and long-term safety. This is needed for older populations who are at greater risk for developing shingles and suffering from its dire side effects.
   
• Compared to live attenuated vaccines, recombinant vaccines are more preferred because they require fewer follow-up and booster doses as they provide longer immunity.
   
• Moreover, GlaxoSmithKline, which produces Shingrix, and other pharmaceutical companies focusing on recombinant vaccines have improved their supply and distribution processes, making these markets more global, so there is a huge availability of recombinant vaccines.
   
• Furthermore, collaborations with pharmacies, public health, and other healthcare providers have enabled many people to get recombinant vaccines, making them readily available and improving their market hold.
   

North America shingles vaccine market accounted for USD 2.7 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 9.6% between the 2025 – 2034 period.
 

• The global market for shingles vaccines is majorly focused on North America, where the underlying cause is the above-average public knowledge, very beneficial policy measures, and robust public health support. The government in the U.S., through the CDC, encourages vaccination of older adults above the age of 50, resulting in higher usage of vaccines like Shingrix.
   
• In addition, coverage of the shingles vaccination under Medicare and other private insurance makes it beneficial and increases the propensity of vaccination among elderly adults. Due to the rapid aging of the population and the support of public health measures, North America is still one of the top regions in the modality for shingles vaccines.
   

France shingles vaccine market is projected to grow remarkably in the coming years.
 

• French health authorities understand the shingles disease and its complications, especially postherpetic neuralgia, that usually makes it harder for elderly people.
   
• The national public health system facilitates vaccination services, which include encouraging vaccination via subsidizing and buying insurance so that it can reach as many people who need it as possible.
   
• This much support from the public health system and the old age population makes France’s share in the European market for shingles vaccines go up.
   
• Severe market share of the Asia Pacific market rests with Japan.
   

Japan holds a dominant position in the Asia Pacific shingles vaccine market.
 

• Japan has one of the largest ratios of the aged in the world, and as such, the country faces a significant public health challenge with attempting and managing the complexities associated with shingles. To aid this issue, the healthcare authorities of Japan have been vigorously recommending the shingles vaccination for senior citizens.
   
• Shingles vaccination has become easier. The government has worked very hard to raise awareness about and increase coverage for the vaccine while bolstering existing monitoring systems to strengthen health service delivery and public health initiatives. Along with this elderly healthcare strategy, Japan has been quite effective in capturing a large proportion of the market for shingles vaccines.
   

Shingles Vaccine Market Share

Competition in the market remains strong, with the top companies investing in product development, forming strategic alliances, and increasing their footprint within the market. The market is dominated by GSK, who possesses the Shingrix vaccine, which has proven to be more effective than all other vaccines in preventing herpes zoster and its sequelae. In addition, health institutions such as the CDC have made recommendations for more widespread use of Shingrix, which further elevates its position in the North American and European markets. Merck is another key player with Zostavax, a highly effective vaccine too, but has been rendered obsolete by Shingrix due to its effectiveness. Competition is fierce between companies trying to increase vaccine availability, vaccination coverage, and insurance coverage among wider populations.
 

Shingles Vaccine Market Companies

Prominent players operating in the shingles vaccine industry include:

• GSK plc
• Merck & Co.
• SK bioscience
   

USP For the Top Players:

• Comprehensive portfolio of shingles vaccines addressing diverse patient needs.
   
• Strong clinical trial data supporting vaccine efficacy and safety.
   
• Extensive global distribution network ensuring wide accessibility.
   

Shingles Vaccine Industry News: 

• In April 2023, GlaxoSmithKline Pharmaceuticals Ltd. (GSK) announced the launch of its shingles vaccine in India. This product launch helped the company to expand its customer base and generate enhanced revenue.
   
• In January 2023, SK bioscience announced that the company had received a biologics license application approval for the SKYZoster from the National Pharmaceutical Regulatory Agency (NPRA) in Malaysia. This strategy helped the company to gain a competitive edge over its peers.
   

The shingles vaccine market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Shingrix
• Zostavax
• SKYZoster

Market, By Vaccine Type

• Recombinant vaccine
• Live attenuated vaccine

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE